Screener
BridgeBio Pharma BBIO Deferred royalty obligations, current portion
Deferred royalty obligations, current portion at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeferredRoyaltyObligationsCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued rebates and other related costs | $79,967 | $45,909 |
| Accrued commercial | 52,167 | 35,773 |
| Deferred royalty obligations, current portion (1) | 29,283 | 11,221 |
| Accrued interest | 16,532 | 14,411 |
| Accrued professional services | 7,778 | 3,665 |
| Other accrued liabilities | 6,459 | 9,243 |
| Total other current liabilities | $192,186 | $120,222 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's deferred royalty obligations, current portion?
- BridgeBio Pharma (BBIO) reported deferred royalty obligations, current portion of $29.28M in Q2 2026.
- What does deferred royalty obligations, current portion mean?
- Deferred royalty obligations, current portion as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's deferred royalty obligations, current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude